2301 GMT - Investors seeking ALS's leverage to the exploration cycle and strong gold price would have been encouraged by the lab-testing company's 1H result, Macquarie says. ALS raised a forecast for revenue growth in FY 2026, benefiting from tailwinds in its Commodities division. ALS now expects organic revenue growth of 12%-14% from the division in FY 2026. Previously, the company had projected growth of 5%-7%. "Pricing is now starting to improve with prices on recent contracts +4-5% as market tightens and consistent with procyclical nature," Macquarie says. "This bodes well for FY 2027 and we factor 20% Commodities Ebit growth on a 14% revenue lift (FY 2027 estimate)." (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
November 18, 2025 18:01 ET (23:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.